Medical researchers at the University of Alberta have published evidence that the orphan generic drug Dichloroacetate (DCA) might be a potential therapy for perhaps the deadliest of all human cancers: a form of brain cancer called glioblastoma.
The report was published in yesterday’s edition of Science Translational Medicine, a journal of the American Association of the Advancement of Science.
The multidisciplinary team led by Evangelos Michelakis, published evidence in 2007 that DCA reverses cancer growth in non-human models and test tubes.
DCA alters the metabolism of cancer and the way cancer handles its nutrient fuels, specifically sugars. DCA was able to take away cancer’s most important strength, the resistance to death. Since then, several independent groups across the world have confirmed the findings of the University of Alberta researchers.
In the study published today, the U of A team found that DCA works the same way in patients as it worked in lab models. In a small clinical trial the researchers provided evidence that DCA may be safe and potentially effective in some patients with advanced glioblastoma.